Olema Pharmaceuticals, Inc. (OLMA)
NASDAQ: OLMA · Real-Time Price · USD
25.36
+0.35 (1.40%)
At close: Feb 6, 2026, 4:00 PM EST
24.87
-0.49 (-1.93%)
After-hours: Feb 6, 2026, 6:42 PM EST
Olema Pharmaceuticals Employees
Olema Pharmaceuticals had 122 employees as of September 30, 2025. The number of employees increased by 34 or 38.64% compared to the same quarter last year.
Employees
122
Change
34
Growth
38.64%
Revenue / Employee
n/a
Profits / Employee
-$1,229,156
Market Cap
1.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 122 | 34 | 38.64% | 122 | 0 |
| Jun 30, 2025 | 117 | 28 | 31.46% | 116 | 1 |
| Mar 31, 2025 | 102 | 26 | 34.21% | 101 | 1 |
| Dec 31, 2024 | 96 | 22 | 29.73% | 96 | 0 |
| Sep 30, 2024 | 88 | 18 | 25.71% | 87 | 1 |
| Jun 30, 2024 | 89 | 17 | 23.61% | 80 | 9 |
| Mar 31, 2024 | 76 | 13 | 20.63% | 75 | 1 |
| Dec 31, 2023 | 74 | -12 | -13.95% | 74 | 0 |
| Sep 30, 2023 | 70 | -5 | -6.67% | 70 | 0 |
| Jun 30, 2023 | 72 | -3 | -4.00% | 67 | 5 |
| Mar 31, 2023 | 63 | -8 | -11.27% | 62 | 1 |
| Dec 31, 2022 | 86 | 12 | 16.22% | 83 | 3 |
| Sep 30, 2022 | 75 | 14 | 22.95% | 73 | 2 |
| Jun 30, 2022 | 75 | 24 | 47.06% | 72 | 3 |
| Mar 31, 2022 | 71 | 34 | 91.89% | 70 | 1 |
| Dec 31, 2021 | 74 | 37 | 100.00% | 73 | 1 |
| Sep 30, 2021 | 61 | 51 | 510.00% | 60 | 1 |
| Jun 30, 2021 | 51 | 41 | 410.00% | 50 | 1 |
| Mar 31, 2021 | 37 | - | - | 36 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Recursion Pharmaceuticals | 800 |
| Vericel | 357 |
| Nuvation Bio | 291 |
| Ocular Therapeutix | 274 |
| Harmony Biosciences Holdings | 268 |
| Soleno Therapeutics | 152 |
| Aurinia Pharmaceuticals | 130 |
OLMA News
- 3 days ago - Olema Oncology to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 days ago - Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 8 days ago - Olema Oncology Announces Departure of Chief Operating and Financial Officer - GlobeNewsWire
- 16 days ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 23 days ago - Olema Pharmaceuticals, Inc. (OLMA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Olema: 'Strong Buy' Maintained On OPERA-02 Trial Initiation & Additional Shots On Goal - Seeking Alpha
- 2 months ago - Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire